These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 7763091)

  • 1. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Arch Dermatol Res; 1995; 287(2):193-7. PubMed ID: 7763091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma.
    Ihn H; Fujimoto M; Sato S; Kikuchi K; Igarashi A; Soma Y; Takehara K
    J Am Acad Dermatol; 1994 Oct; 31(4):591-5. PubMed ID: 7916356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.
    Needleman BW; Wigley FM; Stair RW
    Arthritis Rheum; 1992 Jan; 35(1):67-72. PubMed ID: 1731816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
    Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
    Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
    J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies in childhood scleroderma.
    Bernstein RM; Pereira RS; Holden AJ; Black CM; Howard A; Ansell BM
    Ann Rheum Dis; 1985 Aug; 44(8):503-6. PubMed ID: 3875322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma.
    Davis K; Boros P; Keltz M; Unkeless JC; Fleischmajer R
    J Am Acad Dermatol; 1995 Oct; 33(4):612-6. PubMed ID: 7673494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.
    Yamane K; Ihn H; Kubo M; Kuwana M; Asano Y; Yazawa N; Tamaki K
    Rheumatology (Oxford); 2001 Jun; 40(6):683-6. PubMed ID: 11426027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen specificity of antihistone antibodies in localized scleroderma.
    Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    Arch Dermatol; 1994 Oct; 130(10):1273-7. PubMed ID: 7524451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiubiquitin antibody in localised and systemic scleroderma.
    Fujimoto M; Sato S; Ihn H; Kikuchi K; Tamaki T; Tamaki K; Takehara K
    Ann Rheum Dis; 1996 Jun; 55(6):399-402. PubMed ID: 8694581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma.
    Hasegawa M; Sato S; Nagaoka T; Fujimoto M; Takehara K
    Dermatology; 2003; 207(2):141-7. PubMed ID: 12920362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
    Lis A; Brzezińska-Wcisło L
    Pol Merkur Lekarski; 2001 Sep; 11(63):206-9. PubMed ID: 11761811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis.
    Alecu M; Geleriu L; Coman G; Gălăţescu L
    Rom J Intern Med; 1998; 36(3-4):251-9. PubMed ID: 10822522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma.
    Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Am Acad Dermatol; 1994 Oct; 31(4):567-71. PubMed ID: 8089281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinuclear antibodies in localized scleroderma.
    Takehara K; Moroi Y; Nakabayashi Y; Ishibashi Y
    Arthritis Rheum; 1983 May; 26(5):612-6. PubMed ID: 6405756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD4 and CD8 in serum from patients with localized scleroderma.
    Sato S; Fujimoto M; Kikuchi K; Ihn H; Tamaki K; Takehara K
    Arch Dermatol Res; 1996 Jun; 288(7):358-62. PubMed ID: 8818182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinucleosome antibody is a major autoantibody in localized scleroderma.
    Sato S; Kodera M; Hasegawa M; Fujimoto M; Takehara K
    Br J Dermatol; 2004 Dec; 151(6):1182-8. PubMed ID: 15606513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid antibody in localised scleroderma.
    Sato S; Fujimoto M; Hasegawa M; Takehara K
    Ann Rheum Dis; 2003 Aug; 62(8):771-4. PubMed ID: 12860735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.